In the second part of Generics Bulletin’s Top 50, we look at the mid-table players and how they have shifted positions this year.
With two new spaces having opened up in our rundown of the top 10 generics and biosimilars companies this year – allowing Dr Reddy’s and Cipla to ascend out of the middle table covering positions 11-30 in our ranking, and into the top 10 (see sidebar) – this has left room for further firms to climb up the charts in the second part of the Generics Bulletin Top 50.
Intas – parent company of Accord – now tops the second table, providing financial details directly to Generics Bulletin. The...
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.
Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.
